XML 70 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration and License Agreements - Additional Information (Details)
$ / shares in Units, $ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2025
USD ($)
undisclosedProgram
geneTherapyProgram
preclinicalCandidate
non-clinicalStageCompound
Mar. 31, 2024
USD ($)
Mar. 31, 2023
$ / shares
shares
Dec. 31, 2022
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
Dec. 31, 2019
$ / shares
shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenues $ 572.6 $ 515.3        
Collaborative Arrangement | Common Stock | Voyager            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Beneficial ownership (as a percent)     19.90%      
Nxera | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 2,500.0          
Agreement termination, minimal contractual time (in days) 180 days          
Agreement termination, contractual time threshold (in days) 90 days          
Agreement termination by counterparty, contractual time threshold (in days) 365 days          
Agreement termination by counterparty, minimal contractual time (in days) 120 days          
Takeda | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 700.0          
Agreement termination, minimal contractual time (in days) 6 months          
Agreement termination, contractual time threshold (in days) 12 months          
Number of non-clinical stage compounds | non-clinicalStageCompound 3          
Research and development $ 37.5          
Xenon | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 1,700.0          
Agreement termination, contractual time threshold (in days) 90 days          
Research and development $ 7.5          
Number of preclinical candidates | preclinicalCandidate 3          
Sale of stock (in shares) | shares       300,000 300,000 1,400,000
Share price (in USD per share) | $ / shares       $ 31.855 $ 19.9755 $ 14.196
Voyager | Collaborative Arrangement | Common Stock            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Sale of stock (in shares) | shares     4,400,000     4,200,000
Transfer, beneficial ownership, and voting restrictions period (in years)     3 years      
2019 Voyager Agreement | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 1,300.0          
Agreement termination, minimal contractual time (in days) 180 days          
Agreement termination, contractual time threshold (in days) 1 year          
Research and development   5.0        
Share price (in USD per share) | $ / shares           $ 11.9625
Number of undisclosed programs | undisclosedProgram 2          
2023 Voyager Agreement | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 6,100.0          
Agreement termination, minimal contractual time (in days) 180 days          
Agreement termination, contractual time threshold (in days) 1 year          
Share price (in USD per share) | $ / shares     $ 8.88      
Number of gene therapy programs | geneTherapyProgram 3          
Board of directors maximum duration term (in years)     10 years      
Sanofi S.A | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments $ 10.0          
Sanofi S.A | Collaborative Arrangement | Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalties at tiered percentage 3.00%          
Sanofi S.A | Collaborative Arrangement | Minimum | Patents            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Patent term (in years) 16 years          
Sanofi S.A | Collaborative Arrangement | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalties at tiered percentage 5.00%          
MTPC | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Agreement termination, contractual time threshold (in days) 180 days          
Potential milestone payment receipts $ 30.0          
MTPC | Collaborative Arrangement | Minimum | Patents            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Patent term (in years) 10 years          
AbbVie | Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Agreement termination, contractual time threshold (in days) 180 days          
Potential milestone payment receipts $ 366.0          
AbbVie | Collaborative Arrangement | Royalty            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Total revenues $ 6.7 $ 3.0        
AbbVie | Collaborative Arrangement | Minimum | Patents            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Patent term (in years) 10 years